Ombitasvir is no longer marketed in the United State. It has not been studied in nursing mothers being treated for hepatitis C infection. Because it is 99.9% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. Ritonavir used as a booster has been studied in several studies of breastfeeding mothers. It is excreted into milk in measurable concentrations and low levels can be found in the blood of some breastfed infants. No reports of adverse reactions in breastfed infants have been reported. For more information, refer to the LactMed record on ritonavir. Hepatitis C is not transmitted through breastmilk and breastmilk has been shown to inactivate hepatitis C virus (HCV).[1–4] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to mothers who are being treated for hepatitis C. Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic acid testing is recommended.[1,4]
奥比他韦在美国已不再上市。尚未对接受丙型肝炎感染治疗的哺乳期母亲进行研究。由于它与母体血浆蛋白的结合率为99.9%，母乳中的含量可能非常低。用作增效剂的利托那韦已在多项针对哺乳期母亲的研究中进行了研究。它以可测量的浓度排泄到乳汁中，在一些母乳喂养婴儿的血液中可发现低水平的利托那韦。尚未有关于母乳喂养婴儿出现不良反应的报告。更多信息，请参考利托那韦的《药物和母乳喂养数据库》记录。丙型肝炎不会通过母乳传播，并且已证明母乳可使丙型肝炎病毒（HCV）失活。[1-4]然而，疾病控制中心建议，丙型肝炎感染母亲如果乳头皲裂或出血，应考虑停止母乳喂养。尚不清楚此警告是否适用于正在接受丙型肝炎治疗的母亲。丙型肝炎感染母亲所生的婴儿应进行丙型肝炎感染检测；由于母体抗体在婴儿出生后的前18个月存在，且在婴儿产生免疫反应之前，建议进行核酸检测。[1,4]
